본문 바로가기

TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY One-Year Results

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
피인용
Web of Science 14
JCR IF
JCR 2016 3.7
ISSN
0275-004X

저자

  1. 박강윤제1저자부산대학교, 부산대학교병원, 대학병원, KO
  2. 박성후부산대학교, 의과대학, 의학과, KO
  3. 변익수부산대학교, 의과대학, 의학과, KO
  4. 이지은교신저자부산대학교, 의과대학, 의학과, 안과학교실, KO

초록

Purpose: To investigate the efficacy of a treat-and-extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV). Methods: We retrospectively reviewed the medical records of 29 patients with PCV, who had been treated with a TER for 1 year. The primary outcome was the proportion of eyes that did not lose $ 3 best-corrected visual acuity (BCVA) lines. The number of intravitreal injections and recurrences as well as the maximum treatment interval without recurrence were analyzed. Results: The mean BCVA improved from 0.64 +/- 0.42 logMAR (median, 20/80) at baseline to 0.30 +/- 0.31 logMAR (median, 20/30) at 12 months (P < 0.001). The mean central subfield macular thickness improved from 307.0 +/- 70.2 mu m to 237.5 +/- 64.4 mu m (P < 0.001). None of the subjects lost $ 3 lines, and 15 (51.7%) gained >= 3 lines. The mean number of injections was 7.0. The mean maximum treatment interval without recurrence was 10.0 weeks. After the loading phase, 12 eyes (41.4%) showed no recurrence. Seven eyes (24.1%) demonstrated disease activity at 12 months, and 4 (13.8%) of them were never dry during the entire 12-month follow-up duration. Conclusion: The TER effectively improved visual acuity in PCV while reducing the number of injections.

키워드

polypoidal choroidal vasculopathytreat-and-extendVERTEPORFIN PHOTODYNAMIC THERAPYMACULAR DEGENERATION

식별자

WoS UID
000397987600030